FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer

@article{Jones2015FOXA1RA,
  title={FOXA1 regulates androgen receptor variant activity in models of castrate-resistant prostate cancer},
  author={D. Jones and M. Wade and S. Nakjang and Lewis Chaytor and James Grey and C. Robson and L. Gaughan},
  journal={Oncotarget},
  year={2015},
  volume={6},
  pages={29782 - 29794}
}
Retention of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the requirement for the development of more effective AR targeting therapies. A key mechanism of resistance to anti-androgens is through expression of constitutively active AR variants (AR-Vs) that are refractory to next-generation therapies, including Enzalutamide and Abiraterone. By maintaining an androgenic gene signature, AR-Vs drive tumour survival and progression in castrate conditions… Expand
The Pioneering Role of GATA2 in Androgen Receptor Variant Regulation Is Controlled by Bromodomain and Extraterminal Proteins in Castrate-Resistant Prostate Cancer
Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities
AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer
Differential regulation of the androgen receptor by protein phosphatase regulatory subunits
...
1
2
3
...

References

SHOWING 1-10 OF 48 REFERENCES
Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer
Androgen receptor-independent function of FoxA1 in prostate cancer metastasis.
Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
Targeting the androgen receptor pathway in prostate cancer.
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.
FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
...
1
2
3
4
5
...